Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q1 2025 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, May 2025
Slide 1: Financial Results First Quarter 2025
FINANCIAL RESULTS FIRST QUARTER 2025
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Contents
CONTENTS → 1Q 2025 Results → Results statement and balance sheet for 1Q 2025 → Evolution of RJF shares 3
Slide 4: 1Q 2025 Results: Reig Jofre's net profit grows by 12%
1Q 2025 RESULTS Reig Jofre’s net profit grows by 12% Sed ut perspiciatis → Sales figures for the first quarter of 2024 increase by +2% compared to the same period SALES in 2024. Growth was led by the Consumer Healthcare Division +9%. Specialty Pharmacare grew by 1% affected by lower prices in osteoa
Slide 5: Flash Results 1Q2025 vs. 1Q2024
FLASH RESULTS 1Q2025 VS. 1Q2024 OPERATING SALES FIGURES NET RESULT RESULT €88M €3.7M +2% €3.8M -15% +12% CDMO €14M /-10% OPERATING CASH EBITDA NFD/EBITDA INNOVATION IN RJF moderates its INNOVATION IN PRODUCT FLOW sales growth in a first 9.9BRAND €AND INNOVATION MIN PRODUCT1.5XSPECIALISED INDUSTRIAL
Slide 6: Business Units 1Q2025
BUSINESS UNITS 1Q2025 millions of euros SALES 1Q2025 €88M +2% PHARMACEUTICAL 40% SPECIALITY 34% CONSUMER 26% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €35.7M / –2% €29.8M / +1% €22.5M / +9% Antibiotics 39% Dermatology 32% ENT RJ 17% Injectables Forté Pharma food 54% Osteoarticular 55% 83% and l
Slide 7: Business Units 1Q2025
BUSINESS UNITS 1Q2025 millions of euros SALES 1Q2025 €88M +2% PHARMACEUTICAL 40% SPECIALITY 34% CONSUMER 26% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC €35.7M / –2% €29.8M / +1% €22.5M / +9% • Sales of antibiotics fell by 20% due to an internal • Dermatology grew by +33%, led by sales of • In th
Slide 8: International Presence: Sales 1Q2025
INTERNATIONAL TOTAL PRESENCE Sed ut perspiciatis SALES 1Q2025 Spain Rest of Sed ut perspiciatis Europe Rest of the world SALES GROWTH 1Q2025 +70 COUNTRIES € 88 M €35M 40% €43M 49% €10M 11% -10% +12% +10% Asia 7% Rest of Europe 49% Rest of the world 4% In the first quarter of the year, RJF reduced it
Slide 9: Income Statement
INCOME STATEMENT • Sales figures increased by 2% with an associated gross PÉRDIDAS Y GANANCIAS (miles de euros) 31/03/2025 31/03/2024 V% margin of 60%, the same level as in the previous year. Importe neto de la cifra de negocios 87.953 86.437 2% Coste de las Ventas (35.130) (34.391) 2% • Personnel e
Slide 10: Balance Sheet: Assets and Investments 1Q2025
BALANCE SHEET INVESTMENTS 1Q2025 ASSETS AND INVESTMENTS Millions of euros BALANCE DE SITUACIÓN (miles de euros) 31/03/2025 31/12/2024 Fondo de comercio 27.111 26.809 INDUSTRIAL Otros activos intangibles 54.026 55.285 CAPEX Inmovilizado material 95.853 97.030 2,5 Inversiones contab. método Participac
Slide 11: Balance Sheet: Liabilities and Debts
BALANCE SHEET LIABILITIES AND DEBTS GROSS FINANCIAL DEBT BALANCE DE SITUACIÓN (miles de euros) 31/03/2025 31/12/2024 9.1 TOTAL PATRIMONIO NETO 218.464 213.950 65.2 DEBT LEASES APPLICATION IFRS 16 In millions of € Subvenciones 3.556 3.620 In millions of € Provisiones 225 225 DEBT WITH CREDIT INSTITUT
Slide 12: Evolution of Market Capitalisation
EVOLUTION OF MARKET CAPITALISATION €235M RJF YTD SHARES YTD APR 25 VOLUME CASH RJF (ISIN ES0165359029) €2.91/Share - 30/04/2025 VALUATION maximum minimum 2.4 M €6.3 M €2.67/Share €2.97/Share €2.48/Share YTD Titles YTD SHAREHOLDER COMPOSITION Weighted average 24/04/2025 16/01/2025 28 k titles €76 k Y
Slide 13: Relevant Events After the Accounting Closing of Q1 25
RELEVANT EVENTS • REIG JOFRE will receive €13 million in funding from CDTI* as an associated member AFTER THE of the European IPCEI Med4Cure** project. This amount represents 50% of the ACCOUNTING value of the submitted project, highlighting the strong alignment and quality of its proposal. CLOSING
Slide 14: Alternative Performance Measures
ALTERNATIVE PERFORMANCE Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and MEASURES its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 15: Links and Complementary Information
LINKS AND INFORMATION → RESULTS WEBCAST COMPLEMENTARY https://reigjofre.com/es/inversores/webcasts/ https://reigjofre.com/es/inversores/presentaciones/ → SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre
Slide 16: Thank You
THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN www.reigjofre.com Investor Relations investors@reigjofre.com